传奇生物的 CARVYKTI® 证明二线多发性骨髓瘤患者的总生存期显著改善。 Legend Biotech's CARVYKTI® proves significant overall survival improvement in second line multiple myeloma patients.

传奇生物的 CARVYKTI® 是第一个被证明可以显着提高多发性骨髓瘤患者总生存期的细胞疗法，从二线治疗开始。 Legend Biotech's CARVYKTI® is the first cell therapy proven to significantly improve overall survival in multiple myeloma patients, starting from the second line of treatment. 这一突破提供了与标准疗法相比的一种新选择,标志着在管理这种癌症方面取得重大进展。 This breakthrough offers a new option compared to standard therapies, marking a significant advancement in the management of this cancer.